Mostrar el registro sencillo del ítem

dc.contributor.authorMontoya, Alonso
dc.contributor.authorHervas, Amaia
dc.contributor.authorFuentes, Joaquin
dc.contributor.authorCardo-Jalon, Esther
dc.contributor.authorPolavieja, Pepa
dc.contributor.authorQuintero, Javier
dc.contributor.authorTannock, Rosemary
dc.date.accessioned2024-07-03T11:01:13Z
dc.date.available2024-07-03T11:01:13Z
dc.date.issued2014
dc.identifier.citationMontoya A, Hervas A, Fuentes J, Cardo Jalon E, Polavieja P, Quintero J, et al. Cluster-randomized, controlled 12-month trial to evaluate the effect of a parental psychoeducation program on medication persistence in children with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat. 2014;10:1081-92.en
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/17332
dc.identifier.urihttp://hdl.handle.net/20.500.12105/19948
dc.description.abstractBackground: This multicenter, cluster-randomized, nonblinded study evaluated the effect of parental psychoeducation on medication persistence among children and adolescents with newly diagnosed attention-deficit/hyperactivity disorder (ADHD). Methods: Patients received standard medication alone or medication plus a parental psychoeducation program, and were followed for 12 months. The primary endpoint was time to withdrawal or termination of medication due to any cause. Secondary endpoints included change in ADHD symptom severity, functional outcome, program satisfaction, and safety. Results: A total of 208 patients completed the study, which was terminated early because recruitment had ceased. At 12 months, there was no significant difference between the psychoeducation and control groups in the proportion of patients who discontinued pharmacologic treatment (13.2% versus 14.3%, respectively; size effect -0.3, P=0.34; hazard ratio 0.72, 95% confidence interval 0.36-1.43). Psychoeducation was associated with a significantly greater improvement in ADHD symptoms but not in functional outcome. Parental satisfaction with psychoeducation was high, and satisfaction with pharmacologic treatment was significantly greater in the psychoeducation group. There were no safety concerns. Conclusion: No significant advantage for parental psychoeducation plus medication over medication alone in terms of time to medication withdrawal was observed. Psychoeducation had inconsistent but interesting effects on other outcomes.en
dc.description.sponsorshipAM and PP are full-time employees of and shareholders in Eli Lilly. AH is a consultant for Eli Lilly, and a consultant and speaker for Shire. In the past 3 years, JF has participated in advisory activities, unrestricted educational activities, and research projects sponsored by Janssen, Eli Lilly, Shire, Roche, and public/not for profit agencies. EC has received compensation for serving as a consultant or speaker. Her institution has received research support or royalties from Eli Lilly, the Health Spanish Ministry Research Fund, the Ministry of Education Grant Research, Shire, and UCB. JQ has served as an investigator for Janssen-Cilag and Shire, and as a speaker for Janssen-Cilag, Shire, and Eli Lilly. RT was a member of the DSM-5 Work Group on ADHD and externalizing disorders, and has received speaker fees for an unrestricted talk, consultancy, and an advisory board meeting from Eli Lilly and Shire in the past 3 years. The authors acknowledge the editorial support provided by David Peters and Sue Chambers of Rx Communications, Mold, UK, which was funded by Eli Lilly and Co.es_ES
dc.language.isoengen
dc.publisherDove Medical Press en
dc.rights.urihttps://creativecommons.org/licenses/by-nc/3.0/*
dc.subjectPsychoeducation
dc.subjectMedication persistence
dc.subjectAttention-deficit/hyperactivity disorder
dc.subjectAdjunctive psychoeducation
dc.subjectParents
dc.titleCluster-randomized, controlled 12-month trial to evaluate the effect of a parental psychoeducation program on medication persistence in children with attention-deficit/hyperactivity disorderen
dc.typeresearch articleen
dc.rights.licenseAttribution-NonCommercial 3.0 Unported*
dc.identifier.pubmedID24966679es_ES
dc.format.volume10es_ES
dc.format.page1081-1092es_ES
dc.identifier.doi10.2147/NDT.S62487
dc.identifier.e-issn1178-2021es_ES
dc.relation.publisherversionhttps://dx.doi.org/10.2147/NDT.S62487en
dc.identifier.journalNeuropsychiatric Disease and Treatmentes_ES
dc.rights.accessRightsopen accessen
dc.identifier.scopus2-s2.0-84902573455
dc.identifier.wos338423300005
dc.identifier.puiL373339437


Ficheros en el ítem

FicherosTamañoFormatoVer

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial 3.0 Unported
Este Item está sujeto a una licencia Creative Commons: Attribution-NonCommercial 3.0 Unported